Pharsight

Androgel patents expiration

ANDROGEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8466137 ABBVIE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8466138 ABBVIE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8741881 ABBVIE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8729057 ABBVIE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8754070 ABBVIE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8466136 ABBVIE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8759329 ABBVIE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8486925 ABBVIE Testosterone gel and method of use
Oct, 2026

(2 years from now)

Androgel is owned by Abbvie.

Androgel contains Testosterone.

Androgel has a total of 8 drug patents out of which 0 drug patents have expired.

Androgel was authorised for market use on 29 April, 2011.

Androgel is available in gel, metered;transdermal, gel;transdermal dosage forms.

Androgel can be used as testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

The generics of Androgel are possible to be released after 12 October, 2026.

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 29 April, 2011

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

More Information on Dosage

ANDROGEL family patents

Family Patents